Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161675 | 1.00 | ACACB (0.41) | ACACBDDB1CRBNFFAR4SOS1 | |
| SCHEMBL31161758 | 1.00 | ACACB (0.41) | ACACBDDB1CRBNFFAR4SOS1 | |
| SCHEMBL31161403 | 0.92 | ACACB (0.39) | ACACBDDB1CRBNSOS1USP2 | |
| SCHEMBL31161170 | 0.92 | ACACB (0.39) | ACACBDDB1CRBNSOS1USP2 | |
| SCHEMBL31161762 | 0.90 | ACACB (0.36) | ACACBDDB1CRBNSOS1CYP3A4 | |
| SCHEMBL31161824 | 0.83 | USP2 (0.33) | FFAR4SOS1USP2ALDH1A1CYP3A4 | |
| SCHEMBL31161833 | 0.83 | USP2 (0.33) | FFAR4SOS1USP2ALDH1A1CYP3A4 | |
| SCHEMBL31161719 | 0.83 | USP2 (0.33) | FFAR4SOS1USP2ALDH1A1CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL31161648 | 0.82 | USP2 (0.36) | FFAR4SOS1USP2ALDH1A1CYP3A4 | |
| SCHEMBL31161717 | 0.82 | DDB1 (0.34) | ACACBDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | ACACB 1882/4885DDB1 3238/4885CRBN 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.